Methods and compositions for inhibiting thrombogenesis
AssigneeHamilton Civic Hospitals Research Development Inc.
InventorsJeffrey I. Weitz, Jack Hirsh
Life of this patent
Estimating the term…
Abstract
Thrombus or clot formation and accretion are inhibited by administering thrombin-displacing substances to a patient. The thrombin-displacing substances comprise either thrombin analogs which bind to the thrombin-binding site on fibrin or fibrin analogs which bind to a fibrin-binding site on thrombin. By displacing the thrombin from clot or thrombus, the thrombin is released into circulation where it is inactivated by endogenous anti-proteinases. The fibrin analogs which bind to the fibrin-binding site on thrombin may be linked to a second binding moiety which binds to and/or inactivates the catalytic site on thrombin to further inhibit thrombosis.
Claims4
A method for displacing thrombin bound to fibrin in thrombus, said method comprising exposing the thrombus to a soluble F.sub.2 fragment from prothrombin in an aqueous environment, which soluble F.sub.2 fragment binds to a fibrin-binding site on thrombin with sufficient affinity to displace thrombin from the thrombus and inhibit thrombin in the aqueous environment from binding to fibrin in the thrombus.
A method for inhibiting thrombus accretion, said method comprising exposing the thrombus to a soluble F.sub.2 fragment from prothrombin which binds to a fibrin-binding site on thrombin with sufficient affinity to displace thrombin from the thrombus.
Dependencies are inferred from the claim text.